Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has filed its 2022 Universal Registration Document with the AMF and its annual report on Form 20-F with the SEC for the year ending December 31, 2022. These filings provide comprehensive insights into the company's operations and financial performance. The Universal Registration Document can be accessed via AMF's website, and the Form 20-F is available on the SEC's website. Innate Pharma is developing innovative immunotherapies, leveraging its proprietary ANKET platform. Its lead program, lacutamab, targets advanced forms of cutaneous and peripheral T cell lymphomas, while collaborating with partners like AstraZeneca.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced an exclusive license agreement with Takeda for developing antibody drug conjugates (ADC) targeting an undisclosed area, focusing on Celiac disease. Takeda will manage the development, manufacturing, and commercialization of products. Innate will receive a $5 million upfront payment and could earn up to $410 million in future milestone payments, plus royalties on net sales. This collaboration aims to leverage Innate's antibody engineering expertise, expanding its scientific applications beyond oncology.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) expanded its collaboration with Sanofi on NK cell engager therapeutics, receiving a €25 million upfront payment. The company also reported encouraging preliminary efficacy data for lacutamab in advanced cutaneous T cell lymphoma, with a global objective response rate (ORR) of 28.6%. Additionally, the first patient was dosed in the Phase 3 PACIFIC-9 trial for lung cancer, triggering a $50 million milestone payment from AstraZeneca. As of December 31, 2022, Innate's cash position was €136.6 million, supporting operations into mid-2025. The company aims for key clinical milestones in 2023.

On March 1, 2023, Innate Pharma SA announced its total number of shares outstanding and voting rights as required by French regulations. The company has 80,218,457 ordinary shares and 6,514 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,976,297, with exercisable voting rights at 80,957,722. Innate Pharma focuses on oncology, striving to improve patient outcomes through therapeutic antibodies. The company has established significant partnerships with major biopharmaceutical firms.

Innate Pharma announced a conference call set for March 23, 2023, at 2 p.m. CET for discussing its financial results for the full year ending December 31, 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Interested parties can join via a webcast or telephone registration. Innate Pharma is focused on developing therapeutic antibodies aimed at enhancing cancer treatment, boasting a diverse pipeline and collaborations with major biopharmaceutical companies like Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) confirms it has no financial exposure to Silicon Valley Bank, which was closed by California authorities. All cash and investments remain secure, unaffected by the bank's receivership. The company has an At-The-Market (ATM) program with SVB Securities, which operates independently and is not impacted by the closure. Innate Pharma maintains a robust liquidity position, ensuring ongoing operations will continue without disruption.

As of February 1, 2023, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reports a total of 80,213,957 ordinary shares outstanding. Additionally, there are 6,514 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 80,971,797, while exercisable voting rights amount to 80,953,222. Innate Pharma specializes in developing therapeutic antibodies targeting cancer, with a focus on natural killer cell biology and tumor microenvironments, collaborating with major biopharmaceutical companies.

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced participation in several upcoming investor conferences, focusing on oncology advancements. The conferences include:

• SVB Securities Global Biopharma Conference: February 14-16, 2023 (virtual)
• Citi's 2023 Virtual Oncology Leadership Summit: February 22, 2023 (virtual)
• H.C. Wainwright Cell Therapy Virtual Conference: February 28, 2023 (virtual)

Innate Pharma specializes in therapeutic antibodies aimed at enhancing cancer treatment. The company is recognized for its innovative approach, particularly regarding Natural Killer cell biology, and maintains significant partnerships with industry leaders.

Innate Pharma announced the expiration of the Hart-Scott-Rodino waiting period, making its licensing agreement with Sanofi effective. This collaboration involves Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® platform. The agreement includes a €25 million upfront payment and up to €1.35 billion in potential milestones, plus royalties on net sales. The ANKET® technology is designed to enhance cancer treatment by utilizing NK cells. Innate Pharma aims to leverage its innovative approach in oncology to address unmet medical needs.